John Terrell, MD
Urology · Fort Smith, ARNPI 1528262318
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,204 of the $12,315 with a category attached, or 74.7%. 31 manufacturers reported payments, led by Coloplast at 48.5% of the total.
Across 393 payments — averaging $31.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$6K
- Procept Biorobotics Corporation$1K
- Boston Scientific$492
- Astellas Pharma US Inc$479
- Johnson & Johnson$460
- Pfizer$349
- plus $3K from 25 others
What the payments were for
- Consulting fees$7206%
- Travel & lodging$2,14417%
- Food & beverage$9,20475%
- Education$2482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 128 | $5,972 |
| Procept Biorobotics Corporation | 18 | $1,460 |
| Boston Scientific | 32 | $492 |
| Astellas Pharma US Inc | 22 | $479 |
| Johnson & Johnson(2 entities) | 23 | $460 |
| Pfizer | 23 | $349 |
| Bayer | 15 | $347 |
| Teleflex LLC | 8 | $300 |
| Sumitomo Pharma America, Inc. | 16 | $298 |
| Medtronic | 15 | $221 |
| Axonics, Inc. | 10 | $220 |
| Rochester Medical Corporation | 11 | $218 |
| Urogen Pharma, Inc. | 9 | $216 |
| Antares Pharma, Inc. | 12 | $197 |
| Myovant Sciences Inc. | 9 | $159 |
| AbbVie(2 entities) | 6 | $123 |
| Blue Earth Diagnostics | 5 | $112 |
| Endo Pharmaceuticals Inc. | 6 | $97 |
| Laborie Medical Technologies Corp. | 1 | $97 |
| Myriad Genetic Laboratories, Inc. | 4 | $76 |
| Ambu Inc. | 2 | $75 |
| Merck | 5 | $73 |
| Olympus America Inc. | 2 | $62 |
| Ferring Pharmaceuticals Inc. | 2 | $50 |
| Dendreon Pharmaceuticals LLC | 2 | $43 |
| Endo USA, Inc. | 2 | $34 |
| Innovation Technologies Inc | 1 | $23 |
| Angiodynamics, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Amgen | 1 | $15 |
| Cook Medical LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$4,031
- AquaBeam Robotic System$978
- AQUABEAM SYSTEM$104
How this compares
$12,315 in reported general payments places this provider in the 65th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 61 | $849,528 |
| NubeqaDarolutamide | 18 | $245,780 |
| ErleadaApalutamide | 13 | $197,014 |
| MyrbetriqMirabegron | 50 | $44,124 |
| GemtesaVibegron | 53 | $27,566 |
| Tamsulosin Hcl | 1,145 | $12,663 |
| Methenamine Hippurate | 62 | $4,332 |
| Solifenacin Succinate | 165 | $3,898 |
| Dutasteride | 92 | $2,100 |
| Finasteride | 165 | $1,895 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 198 | $1,466 |
| Tadalafil | 13 | $1,308 |
| Testosterone Cypionate | 33 | $1,291 |
| Oxybutynin Chloride | 150 | $1,025 |
| Naloxone Hcl | 15 | $1,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $479 | $893,652111 claims |
| BayerNubeqa | $347 | $245,78018 claims |
| Johnson & JohnsonErleada | $460 | $197,01413 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $298 | $27,56653 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 88 urology providers in Arkansas.
Other urology in Fort Smith
- Kyle BashamFort Smith$30K
- Ronald KnoblochFort Smith$5K
- John LangeFort Smith$2K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Ronald KuhnNorth Little Rock$138K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.